This article compiles and summarizes the latest developments in cosmetics regulations in China and globally as of May 2025, covering industry news, newly issued regulations, relevant policy adjustments, and regulatory requirements. It aims to assist enterprises in ensuring compliance and keeping up with global cosmetics regulatory trends.

In order to strengthen cosmetic regulation and safeguard consumer rights, the NMPA's Department of Cosmetics Supervision has provided answers to key industry concerns-such as labeling-based on current Chinese laws and technical standards. CIRS Group has compiled the information and translated them into English for your reference.

Following FAQs are all related to cosmetic safety assessment, CIRS Group has compiled the information and translated them into English for your reference.

On 6 June, 2025, the Scientific Committee on Consumer Safety (SCCS) of the European Union issued preliminary opinion (SCCS/1680/25) on Prostaglandin Analogues: Methylamido-Dihydro-Noralfaprostal (MDN) (CAS No. 155206-01-2), Isopropyl Cloprostenate (IPCP) (CAS No. 157283-66-4) and Dechloro Dihydroxy Difluoro Ethylcloprostenolamide (DDDE) (CAS No. 1185851-52-8). The deadline for comments is set for 18 August 2025.

Based on data retrieved from China’s National Medical Products Administration (NMPA), Shenzhen Dieckmann Biotechnology Co., Ltd. completed the filing of Ceramide EOS as a new cosmetic ingredient on June 10, 2025. At present, the associated technical specifications have not been made public, and the ingredient has not yet entered the post-filing monitoring period.